Circulating adiponectin and leptin in relation to myelodysplastic syndrome: A case-control study

Oncology

Volumn 73, Issue 1-2, 2008, Pages 26-32

  Dalamaga, Maria ^a   Nikolaidou, Athina ^a   Karmaniolas, Konstantinos ^b   Hsi, Alex ^c   Chamberland, John ^c   Dionyssiou Asteriou, Amalia ^a   Mantzoros, Christos S ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b NIMTS HOSPITAL   (Greece)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Adipokine; Adiponectin; Leptin; Myelodysplastic syndromes

Indexed keywords

ADIPONECTIN; LEPTIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BIVARIATE ANALYSIS; BLOOD SAMPLING; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEPTIN; LEUKEMIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OBESITY; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 41549110810     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000120995     Document Type: Article

References (34)

1. Block M, Jacobson LO, Bethard WF: Preleukemic acute human leukemia. J Am Med Assoc 1953;152:1018-1028.
2. List AF, Doll DF: The myelodysplastic syndromes; in Lee GR, Foerster J, Luken J, Paraskevas F, Greer JP, Rodgers GM, Wintrobe MM (eds): Wintrobe's Clinical Hematology. Baltimore, Lippincott Williams & Wilkins, 1999, vol 2, pp 2320-2333.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
4. Aul C, Germing U, Gattermann N, Minning H: Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res 1998;22:93-100.
5. Bennett JM, Komrokji RS: The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 2005;10(suppl 1):258-269.
6. Pasqualetti P, Festuccia V, Acitelli P, Collacciani A, Giusti A, Casale R: Tobacco smoking and risk of haematological malignancies in adults: a case-control study. Br J Haematol 1997;97:659-662.
7. Bjork J, Albin M, Mauritzson N, Stromberg U, Johansson B, Hagmar L: Smoking and myelodysplastic syndromes. Epidemiology 2000;11:285-291.
8. Dalamaga M, Petridou E, Cook FE, Trichopoulos D: Risk factors for myelodysplastic syndromes: a case-control study in Greece. Cancer Causes Control 2002;13:603-608.
9. Ido M, Nagata C, Kawakami N, Shimizu H, Yoshida Y, Nomura T, Mizoguchi H: A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res 1996;20:727-731.
10. Ross JA, Parker E, Blair CK, Cerhan JR, Folsom AR: Body mass index and risk of leukemia in older women. Cancer Epidemiol Biomarkers Prev 2004;13:1810-1813.
11. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, Adam HO: A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13-21.
12. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:1625-1638.
13. Chan JL, Moschos SJ, Bullen J, Heist K, Li X, Kim YB, Kahn BB, Mantzoros CS: Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 2005;90:1625-1631.
14. Matarese G, Moschos S, Mantzoros CS: Leptin in immunology. J Immunol 2005;174:3137-3142.
15. Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M: Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 1999;93:1668-1676.
16. Nakao T, Hino M, Yamane T, Nishizawa Y, Morii H, Tatsumi N: Expression of the leptin receptor in human leukaemic blast cells. Br J Haematol 1998;102:740-745.
17. Chan JL, Matarese G, Shetty GK, Raciti P, Kelesidis I, Aufiero D, De Rosa V, Perna F, Fontana S, Mantzoros CS: Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci USA 2006;103:8481-8486.
18. Chan JL, Bullen J, Stoyneva V, Depaoli AM, Addy C, Mantzoros CS: Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab 2005;90:1618-1624.
19. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D: Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102-1107.
20. Dal ML, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La VC: Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89:1160-1163.
21. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S: Prostate cancer and adiponectin. Urology 2005;65:1168-1172.
22. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H: Plasma adiponectin and gastric cancer. Clin Cancer Res 2005;11:466-472.
23. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS: Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 2007;120:1573-1578.
24. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS: Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005;97:1688-1694.
25. Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D: Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 2006;94:156-160.
26. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-1732.
27. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
28. SAS/STAT User's Guide 6.04. Cary, SAS Institute, 1989.
29. Papathanassoglou E, El-Haschimi K, Li XC, Matarese G, Strom T, Mantzoros C: Leptin receptor expression and signaling in lymphocytes: kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice. J Immunol 2006;176:7745-7752.
30. Brennan AM, Mantzoros CS: Drug insight: the role of leptin in human physiology and pathophysiology-emerging clinical applications. Nat Clin Pract Endocrinol Metab 2006;2:318-327.
31. Mantzoros CS, Trakatelli M, Gogas H, Dessypris N, Stratigos A, Chrousos GP, Petridou ET: Circulating adiponectin levels in relation to melanoma: a case-control study. Eur J Cancer 2007;43:1430-1436.
32. Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Rana-Trejo RM, Mayani H: In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 2002;26:677-686.
33. Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R: Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 2005;75:485-491.
34. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME: Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004;316:924-929.